ReviewJournal of pharmaceutical analysis2025
Natural products based on Correa's cascade for the treatment of gastric cancer trilogy: Current status and future perspective.
Review in Journal of pharmaceutical analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Reframing early gastric carcinogenesis through lineage, niche, and evolution.Cancer metastasis reviews · 2026Review
- Integration of biochemical and pharmacological evaluation of Pistacia lentiscus leaf polysaccharides: evidence for anti-inflammatory and gastroprotective activity.Inflammopharmacology · 2026Article
- Chromosome-scale assembly of the eliteHorticulture research · 2026Article
- An Engineered Nano-Vesicle Adjuvant Platform (ENAP) for Cytokine Delivery Enables a Novel Antigen-Coordinated Vaccine Against Helicobacter pylori.Journal of extracellular vesicles · 2026Article
- Prevention of Gastric Cancer.Medicina (Kaunas, Lithuania) · 2026Review
- Pristimerin ameliorates spasmolytic polypeptide-expressing metaplasia by modulatingWorld journal of gastroenterology · 2026Article
- Impact of incisura biopsy on the surveillance of precursor lesions and gastric cancer risk assessment.Gastroenterology report · 2026Article
- The role of ferroptosis in renal cell carcinoma: molecular mechanisms and therapeutic implications.Journal of molecular medicine (Berlin, Germany) · 2026Review
- Glycolytic reprogramming in precancerous lesions of gastric cancer progression: pathogenesis and therapeutic potential.Frontiers in oncology · 2026Review
- Asiatic acid remodels the gastric precancerous immune microenvironment by targeting STING.Frontiers in immunology · 2026Article
- Formononetin Alleviates MNNG-Triggered Chronic Atrophic Gastritis: Its Potential Mechanisms.Combinatorial chemistry & high throughput screening · 2026Article
- Using Caprylic Acid for the Prevention and Treatment ofMetabolites · 2025Review
- Potential of traditional Chinese medicine in gastrointestinal disorders:World journal of gastroenterology · 2025Article
- Prognostic risk factors analysis of low-grade gastric intraepithelial neoplasia-a single-center follow-up study.Frontiers in medicine · 2025Article
- Comparison of tegoprazan-based high-dose dual therapy versus bismuth-containing quadruple therapy forTherapeutic advances in gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric carcinoma (GC) is a malignancy with multifactorial involvement, multicellular regulation, and multistage evolution. The classic Correa's cascade of intestinal GC specifies a trilogy of malignant transformation of the gastric mucosa, in which normal gastric mucosa gradually progresses from inactive or chronic active gastritis (Phase I) to gastric precancerous lesions (Phase II) and finally to GC (Phase III). Correa's cascade highlights the evolutionary pattern of GC and the importance of early intervention to prevent malignant transformation of the gastric mucosa. Intervening in early gastric mucosal lesions, i.e., Phase I and II, will be the key strategy to prevent and treat GC. Natural products (NPs) have been an important source for drug development due to abundant sources, tremendous safety, and multiple pharmacodynamic mechanisms. This review is the first to investigate and summarize the multi-step effects and regulatory mechanisms of NPs on the Correa's cascade in gastric carcinogenesis. In phase I, NPs modulate
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.